The Role of Growth Factors in Managing Chemotherapy-Induced Cytopenia
Author Information
Author(s): Alyamany Ruah, Alnughmush Ahmed, Alzahrani Hazzaa, Alfayez Mansour
Primary Institution: King Faisal Specialist Hospital and Research Centre
Hypothesis
The use of growth factors can effectively manage chemotherapy-induced cytopenia (CIC) in cancer patients.
Conclusion
Growth factors like GCSFs, ESAs, and TPO-RAs show promise in managing chemotherapy-induced cytopenia but must be used cautiously due to potential risks.
Supporting Evidence
- Chemotherapy-induced cytopenia affects approximately 60% of patients undergoing chemotherapy.
- Growth factors can provide durable relief from chemotherapy's toxic effects.
- GCSFs are effective in reducing the duration of severe neutropenia.
- ESAs improve hemoglobin levels and quality of life in patients with chemotherapy-induced anemia.
- TPO-RAs have shown efficacy in managing chemotherapy-induced thrombocytopenia.
Takeaway
Chemotherapy can make people very sick by lowering their blood cell counts, but special medicines called growth factors can help them feel better and stay on their treatment.
Methodology
This review summarizes existing literature on the mechanisms, efficacy, and safety of growth factors in managing chemotherapy-induced cytopenia.
Potential Biases
Potential risks include increased chances of thrombosis and relapse in certain cancer types.
Limitations
The review does not cover cytopenia in myeloid malignancies and stem cell transplantation, where growth factor use is controversial.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website